Trials / Conditions / Skin Squamous Cell Carcinoma

Skin Squamous Cell Carcinoma

13 registered clinical trials studyying Skin Squamous Cell Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natura NCT07144384	Kirsten Johnson	EARLY_Phase 1
Not Yet Recruiting	NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique NCT06610071	The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Phase 1
Recruiting	EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymph NCT06223659	Ohio State University Comprehensive Cancer Center	Phase 2
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer NCT03944941	Alliance for Clinical Trials in Oncology	Phase 2
Terminated	Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113	SOTIO Biotech AG	Phase 1
Unknown	ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS NCT03822988	Central Hospital, Nancy, France	—
Completed	Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) NCT03353077	Alpha Tau Medical LTD.	N/A
Active Not Recruiting	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625	National Cancer Institute (NCI)	Phase 2
Completed	Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors NCT03108131	M.D. Anderson Cancer Center	Phase 2
Completed	Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer NCT02964559	Emory University	Phase 2
Completed	Oral Rigosertib for Squamous Cell Carcinoma NCT01807546	Traws Pharma, Inc.	Phase 2
Completed	Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer NCT00954226	M.D. Anderson Cancer Center	Phase 1